All Photos
This Juneteenth, we celebrate the Black community’s resilience and enduring hope, and thank our employees for continuing to inspire us to break down systemic barriers to healthcare and advance health equity.
#Breaking: We’re sharing an update on a landmark study evaluating the potential of our investigational medicine to prevent or delay Alzheimer’s disease in people with a specific genetic mutation. Learn more:…
Thank you @FortuneMagazine for including us on the 2022 Best Workplaces in The Bay Area list! We believe in the power of investing in and partnering with our local communities, which is fueled by our passionate employees.
This week, our employees are coming together to volunteer, donate and support our local communities during our annual tradition of giving back. Learn more:
Today we announced new data from our growing #bloodcancer portfolio that broadens our understanding of the impact our medicines have in early phases of disease. Learn more:…
#ASCO22 was filled with great learning and scientific exchange. Seeing so many advancements from across the #oncology community was inspiring, and our drive to deliver innovation and improve outcomes is stronger than ever:
We’re advancing #immunotherapy research and helping to bring new therapies to people living with #cancer. Learn more about the robust field of cancer immunotherapy research here:
Charlie Fuchs, Global Head of Oncology and Hematology for Global Product Development Growth, comments on data we will present at #ASCO22 as part of our commitment to improving standards of care and outcomes for people with blood cancer. Learn more:
A cancer-free tomorrow starts here. Learn how we’re working together to turn science into breakthroughs and build a future where every #cancer story has a better ending:
Cancer care has come a long way. At #ASCO22, we look forward to joining the #oncology community to discuss exciting new research and advancements that can bring more hope to patients than ever before:
Our annual D&I report shared recent progress towards increasing Black/African American and Hispanic/Latinx representation among senior leadership positions. Learn how our Directors Exchange is helping to break down barriers to career advancement:
We're joining the #oncology community this week to kick off #ASCO22. Learn more about our work to power scientific breakthroughs and bring the very best care to each person diagnosed with #cancer:
The introduction of novel approaches to treating non-Hodgkin’s lymphoma like antibody immunotherapies have changed the blood cancer treatment paradigm. See how we’re building on our learnings to redefine standards of care in hematologic cancers: #ASCO22
ICYMI: A supplement for our spinal muscular atrophy (#SMA) medicine was recently approved by the @US_FDA. Read more:…
Differing perspectives and priorities on what constitutes “value” within the healthcare system can lead to a fragmented view of the value medicines deliver for patients and the larger system. Learn how we’re working towards a holistic definition:
This #CFAwarenessMonth, we are partnering with @RoadmapToCF on “We Are The Extended CF Familia” to provide Spanish resources and information for the 3,000 Latinos in the U.S. living with cystic fibrosis. Learn more at
#Breaking: The @US_FDA has approved the supplemental New Drug Application (sNDA) for our spinal muscular atrophy (#SMA) treatment. Read more:…
#Breaking: We’re announcing new pivotal data at #ASCO22 showcasing a potential first-in-class bispecific antibody used to treat people with aggressive lymphoma. Learn more:…
Our scientists are leading the charge in cancer immunotherapy by embracing the potential of human genomics research, which may contribute to the discovery of novel therapeutic targets and yield predictive biomarkers. Read about their research in @CIR_AACR
At #ASCO22 we’ll be presenting pivotal data on one of our #bispecific antibodies and sharing updates from our oncology portfolio, including new #realworlddata and research in comprehensive #genomictesting. Learn more:…
Lélia Delamarre, our Senior Principal Scientist in Cancer Immunology, discussed neoantigens as targets and the potential of personalized cancer vaccines at #AACR. Read about her insights:…
Shannon Turley, our VP & Senior Fellow of Immunology and OMNI Biomarker Discovery, shared her discoveries at #AACR22 on immune interactions in cancer immunotherapy, a crucial part of our mission to advance the future of oncology care. Read about her insights:…
The Genentech Foundation’s latest $5M commitment to @SFSU will help fund scholarships and leading-edge STEM education and equipment for more students, particularly those from historically marginalized groups. Learn more below.…
We strive to foster a workplace where our employees can show up authentically and contribute their unique perspectives. Hear from Diana Auyeung-Kim below. #AAPIHeritageMonth
#Breaking: Today we provided an update on the Phase III trial evaluating our anti-#TIGIT cancer immunotherapy in certain NSCLC patients. Learn more:…
Some people with severe asthma don’t benefit from current medicines. In @ScienceTM, our scientists Riccardo Guidi, Mark Wilson & team investigated mechanisms behind poor medication responses, providing insight for new therapeutics based on their findings.
ICYMI: Our scientists Michael Koehler & Melicent Peck discuss innovation amid antibiotic resistance, the economics of developing new antibiotics, and stewardship to ensure responsible and safe treatment in S4E05 of our #podcast. Listen here:
In the latest episode or our #podcast, our scientists Michael Koehler and Melicent Peck explore the incredible adaptability of bacteria & the challenge of antibiotic resistance. Listen to it here:
#Breaking: Today at the @EPNSnews Congress, we announced new 3-year data evaluating our medicine for spinal muscular atrophy (SMA) in infants with symptomatic Type 1 #SMA. Learn more:…
ICYMI: Hear from our Chief Diversity Officer, Quita Highsmith, on her perspective about our second annual D&I report and progress towards advancing diversity, equity and inclusion within our company and beyond. @FiercePharma…
Mark McCarthy, our Executive Director of Human Genetics believes that there are some critical limitations in developing effective medicines that could be improved with studying more diverse genetic data. Learn more here:
We have been recognized by @Forbes as one of the Best Employers for Diversity for the fifth year in a row! It’s an honor to be included among this list of leading companies advancing equity and inclusivity in the workplace. Learn how we foster belonging:
Gene editing is an important research tool, but there are opportunities to improve approaches. In @JExpMed, our scientists describe a convenient, scalable method to knock-in any gene of interest into T cells that could lead to new cancer immunotherapies.
Happy #DNADay! We’re celebrating scientists' discovery of the DNA double helix in 1953! On this special day, learn how our Executive Director of Human Genetics Mark McCarthy is leading our efforts to use genomics to develop safe and effective medicines.
The industry continues to deliver innovative medicines for serious medical conditions. Yet when it comes to paying for these treatments, our reimbursement system has not kept pace with the science. Learn how we’re advocating for drug pricing reforms here:
Cancer cells are good at evading cell death pathways. In @ScienceMagazine, our scientists @RitterLab & team discovered a new way cancer cells protect themselves from the immune system, which may have implications for future immunotherapies.
To celebrate #EarthDay, our employees and Executive Committee members lined up for the climate to show our commitment to a healthy, equitable and sustainable future for all. Learn more about our sustainability goals:
Check out S4E04 of our #podcast, Two Scientists Walk into a Bar, to hear our scientists discuss many of the complexities of #AlzheimersDisease and promising research to advance new treatments:
Other avenues of #AlzheimersDisease research include zeroing in on neuroinflammation and its causes, as well as the microbiome and how it interacts with the brain.
There are many avenues of research in #AlzheimersDisease, such as exploring the role of specialized cells called microglia, which serve as the brain’s primary immune cells, in the development of neurodegenerative diseases.
Over the past decade, scientists around the world have made significant progress in understanding the biology of #AlzheimersDisease.
As part of the Bloomberg New Economy International Cancer Coalition, access to better care is always top of mind. Read more to see how the pandemic is fostering more collaboration and paving more ways to get medicines to patients faster below.…
The high cost of healthcare in the U.S. has rightfully spurred a call to action for pricing and payment reforms that advance a more accessible, affordable and sustainable healthcare ecosystem. Hear more from our CEO, Alexander Hardy.
Shout out to our scientist, @RitterLab, for sharing this excellent example of how killer T cells target cancer cells. 👏 Thanks for sharing, Alex!…w
Read about our equity-focused giving and funding process for the 2022 Health Equity & Diversity in STEM Innovation Fund and see how we’re investing in bold ideas and the people who power them:
Today we launched our biennial Health Equity & Diversity in STEM Innovation Fund which will award $12M+ to applicants proposing novel solutions to improve equity in clinical research/care delivery & diversify the scientific/medical workforce. Learn more:
Our research in neurological conditions is moving us forward, even if that means changing course. Gregory A. Rippon, VP, Chief Medical Partner, shares how we maintain persistence to develop transformational medicines.
Research has shown the biological clock in older cells can be reset. In a @NatureAging paper, our scientists & @salkinstitute reprogrammed cells to reduce age-related changes in mice & boost regenerative effects like in the skin pictured below. Learn more:
ICYMI: Our scientists recently published their insights on how RNA vaccines induce innate immunity, the latest in our efforts to explore how this technology can advance personalized cancer treatments. Learn more about their work:
ICYMI: The sBLA for our #COVID19 medicine was accepted by the @US_FDA. If approved, it would be the first FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized adults. Learn more:…
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome